Pharma-Bio Serv Amends 10-K to Disclose Significant Related-Party AI Investment and Executive Compensation

summarizeSummary

Pharma-Bio Serv filed an amended 10-K to include executive and director compensation details, security ownership, and a significant related-party investment in an AI company co-managed by a director.

check_boxKey Events

• Amended Annual Report Filed

  This Form 10-K/A completes the annual report for the fiscal year ended October 31, 2025, by providing the information required by Items 10 through 14 of Part III, which was omitted from the original filing on January 29, 2026.

• Significant Related-Party AI Investment

  The company entered into an agreement on August 19, 2024, to pay $250,000 for the development of an AI-based 'Lead Generation Technology Platform' and a 2.44% membership interest in the AI Company. A director, Dov Perlysky, and his brother-in-law indirectly hold a minority interest and are indirect managers of this AI Company. The agreement also includes a two-year option to acquire an additional 16.67% interest for $1,750,000.

• Executive Compensation Details

  CEO Victor Sanchez received an annual salary of $231,000 and a $600 bonus, totaling $245,900 for fiscal year 2025. CFO Pedro Lasanta received an annual salary of $175,000 and a $600 bonus, totaling $175,600.

• Director Compensation Outlined

  Independent directors received a $12,500 quarterly retainer fee ($50,000 annually) and an automatic annual stock option grant valued at $6,320 (grant date fair value) for fiscal year 2025.

auto_awesomeAnalysis

This 10-K/A filing completes the annual report by providing previously omitted Part III information, which includes critical details on executive compensation, director remuneration, and security ownership. The most significant new disclosure is a substantial related-party agreement where Pharma-Bio Serv invested $250,000 for an AI platform and a 2.44% stake in a company co-managed by a director, with an option for an additional 16.67% interest for $1,750,000. This represents a material capital outlay relative to the company's market capitalization and introduces potential conflicts of interest due to the related-party nature. Investors should scrutinize the terms and strategic value of this AI investment.